05/17/22 7:01 AMNasdaq : MDWD low floatMediWound Announces CEO TransitionMediWound Ltd. (Nasdaq: MDWD), a fully-integratedRHEA-AIvery positive
05/17/22 7:00 AMNasdaq : MDWD earningslow floatMediWound Reports First Quarter 2022 Financial ResultsMediWound Ltd. (NASDAQ: MDWD), a fully-integratedRHEA-AIneutral
05/12/22 7:00 AMNasdaq : MDWD clinical triallow floatMediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic WoundsStudy Met Primary and Key Secondary Endpoints with Statistically Significant Results Compared to Control Arms Significant Improvement Across Multiple Measures Over the Current Non-Surgical Standard-of Care No Deleterious Effect on Wound Closure and No Observed Safety Issues End of Phase 2 MeetingRHEA-AIneutral
05/10/22 4:01 PMNasdaq : MDWD conferencesearningslow floatMediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the firstRHEA-AIneutral
04/12/22 8:00 AMNasdaq : MDWD low floatMediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical companyRHEA-AIpositive
03/29/22 8:00 AMNasdaq : MDWD conferencesclinical triallow floatMediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeuticRHEA-AIpositive
03/22/22 4:05 PMNasdaq : MDWD low floatMediWound Announces Exercise of Over-Allotment OptionMediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that the underwriter ofRHEA-AIneutral
03/21/22 7:30 AMNasdaq : MDWD clinical triallow floatMediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic WoundsMediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeuticRHEA-AIneutral
03/17/22 7:00 AMNasdaq : MDWD earningslow floatMediWound Reports Fourth Quarter and Full Year 2021 Financial ResultsFull-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of $10 Million through Public Equity Offering Conference Call Begins Today at 8:30 am ETRHEA-AIneutral
03/10/22 5:05 PMNasdaq : MDWD offeringlow floatMediWound Announces Closing of Public Offering of Ordinary SharesMediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that on March 7, 2022 itRHEA-AIneutral